Bloomberg @business
The head of the FDA is facing questions from a top lawmaker about the agency’s response to a report that UK drugmaker GSK hid and downplayed cancer risks from Zantac, its blockbuster heartburn drug, for four decades https://t.co/ZVk1FL7yon — PolitiTweet.org